Digital Doublespeak: The Language Barrier When Tech Companies Meet Regulators
Executive Summary
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”
You may also be interested in...
COVID-19 Trial Changes Are "Propulsive Force" For Digital Adoption
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
US FDA Outlines Wishlist For Decentralized Clinical Trials
As interest in conducting remote decentralized clinical trials grows, a senior US regulator explains what companies should consider when planning such trials.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.